irinotecan has been researched along with Hematologic Malignancies in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cardillo, TM; Chang, CH; Goldenberg, DM; Govindan, SV; Rossi, DL; Wang, Y; Zalath, MB | 1 |
Cardillo, TM; Goldenberg, DM; Govindan, SV; Sharkey, RM | 1 |
Cottu, PH; Espie, M; Extra, JM; Lerebours, F; Marty, M | 1 |
Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ | 1 |
2 review(s) available for irinotecan and Hematologic Malignancies
Article | Year |
---|---|
[Clinical activity spectrum of irinotecan].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Child; Clinical Trials as Topic; Digestive System Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Hematologic Neoplasms; Humans; Irinotecan; Male; Neoplasm Proteins; Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms | 2001 |
2 other study(ies) available for irinotecan and Hematologic Malignancies
Article | Year |
---|---|
IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Cell Line, Tumor; Hematologic Neoplasms; HLA-DR Antigens; Humans; Immunoconjugates; Immunoglobulin G; Irinotecan; Melanoma; Mice | 2018 |
Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Female; Hematologic Neoplasms; Humans; Immunoconjugates; Irinotecan; Mice; Mice, Nude; Sialic Acid Binding Ig-like Lectin 2 | 2012 |